1.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.
J Viral Hepat. 2004; 11(2) : 97
-107
[PubMed]
2.
European Association for the Study of the Liver . EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
J Hepatol. 2012; 57(1) : 167
-85
[DOI][PubMed]
3.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009.
Hepatology. 2009; 50(3) : 661
-2
[DOI][PubMed]
4.
Liaw YF,
Kao JH,
Piratvisuth T,
Chan HL,
Chien RN,
Liu CJ,
et al.
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.
Hepatol Int. 2012; 6(3) : 531
-61
[DOI][PubMed]
5.
Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.
Hepatology. 2013; 57(1) : 399
-408
[DOI][PubMed]
6.
Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.
J Hepatol. 2000; 32(2) : 300
-6
[PubMed]
7.
Shouval D,
Lai CL,
Chang TT,
Cheinquer H,
Martin P,
Carosi G,
et al.
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
J Hepatol. 2009; 50(2) : 289
-95
[DOI][PubMed]
8.
Hadziyannis SJ,
Tassopoulos NC,
Heathcote EJ,
Chang TT,
Kitis G,
Rizzetto M,
et al.
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
N Engl J Med. 2005; 352(26) : 2673
-81
[DOI][PubMed]
9.
Hadziyannis S, Sevastianos V, Rapti I. 18 Outcome OF HBeAg-Negative Chronic Hepatitis B (CHB) 5 Years After Discontinuation of Long Term Adefovir Dipivoxil (ADV) Treatment.
J Hepatol. 2009; 50[DOI]
10.
Reijnders JG,
Deterding K,
Petersen J,
Zoulim F,
Santantonio T,
Buti M,
et al.
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
J Hepatol. 2010; 52(4) : 493
-500
[DOI][PubMed]
11.
Perry CM, Jarvis B. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
BioDrugs. 2002; 16(3) : 213
-7
[PubMed]
12.
Janssen HL,
van Zonneveld M,
Senturk H,
Zeuzem S,
Akarca US,
Cakaloglu Y,
et al.
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Lancet. 2005; 365(9454) : 123
-9
[DOI][PubMed]
13.
Lau GK,
Piratvisuth T,
Luo KX,
Marcellin P,
Thongsawat S,
Cooksley G,
et al.
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med. 2005; 352(26) : 2682
-95
[DOI][PubMed]
14.
Marcellin P,
Lau GK,
Bonino F,
Farci P,
Hadziyannis S,
Jin R,
et al.
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
N Engl J Med. 2004; 351(12) : 1206
-17
[DOI][PubMed]
15.
Flink HJ,
Hansen BE,
Heathcote EJ,
Feinman SV,
Simsek H,
Karayalcin S,
et al.
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
Am J Gastroenterol. 2006; 101(11) : 2523
-9
[DOI][PubMed]
16.
Sun J,
Hou JL,
Xie Q,
Li XH,
Zhang JM,
Wang YM,
et al.
Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.
Aliment Pharmacol Ther. 2011; 34(4) : 424
-31
[DOI][PubMed]
17.
Zhang XQ, Zhang HY, You JP, Mao Q. Efficacy of pegylated interferon alpha2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.
Virol J. 2013; 10 : 21
[DOI][PubMed]
18.
Liaw YF,
Jia JD,
Chan HL,
Han KH,
Tanwandee T,
Chuang WL,
et al.
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.
Hepatology. 2011; 54(5) : 1591
-9
[DOI][PubMed]
19.
Buster EH,
Hansen BE,
Lau GK,
Piratvisuth T,
Zeuzem S,
Steyerberg EW,
et al.
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Gastroenterology. 2009; 137(6) : 2002
-9
[DOI][PubMed]
LEAVE A COMMENT HERE: